Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
NCT ID: NCT02792764
Last Updated: 2016-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2014-02-28
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Nutritional Status of Chemo-radiotherapy Patients
NCT01937273
Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment
NCT02619045
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
NCT02786524
A Computer-Based System for Symptom Reporting in Patients With Cancer Undergoing Treatment
NCT03979846
Nutrition and Chemotherapy
NCT03840213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Port
Subjects receiving chemotherapy through a port
No interventions assigned to this group
Peripheral Intravenous (PIV) Lines
Subjects receiving chemotherapy through a peripheral IV
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or infusion through a PIV
* Subject had a chemotherapy regimen consisting of a vesicant and/or irritant
* Subject has signed an Informed Consent Form (ICF) or has had an ICF signed by the subject's legally authorized representative
Exclusion Criteria
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
C. R. Bard
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quincy Medical Group
Quincy, Illinois, United States
Willis Knighton Cancer Center
Shreveport, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BPV-13-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.